Solvay

Weaker expectations for the oil & gas business

07/11/19 -"This led to an impairment (92% for goodwill) on the former Rhodia and Chemlogics activities (Novecare – Advance Formulations), which damaged the Q3 figures and came fully out of the blue. In ..."

PDF page sample
Pages
57
Language
English
Published on
07/11/19
Download
You may also be interested by these reports :
11/02/26
Yara International reported Q4 2025 results, supported by CBAM-related pre-buying, with improved price/mix driving margin expansion. However, overall ...
06/02/26
The group reported expected results for FY25. Management anticipates growth in the coming year, slightly exceeding last year’s performance, ...
03/02/26
Akzo reported its FY25 results with adjusted earnings broadly in line with market consensus. Management guides to flat volumes with positive ...
03/02/26
We expect convincing 2Q results. Add – New TP of EUR 78

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO